Otsuka Holdings Co Ltd
TSE:4578
Otsuka Holdings Co Ltd
Revenue
Otsuka Holdings Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Revenue
¥2.3T
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Revenue
¥4.6T
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Revenue
¥1.9T
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Revenue
¥431.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
5%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Revenue
¥1.2T
|
CAGR 3-Years
1%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Revenue
¥1.9T
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
Otsuka Holdings Co Ltd
Glance View
Otsuka Holdings Co. Ltd. began its journey in 1921 as a small chemicals company in Naruto, Japan. Its evolution from those humble beginnings to a global pharmaceutical giant is marked by its relentless commitment to innovation and expansion. Today, Otsuka operates as a holding company, orchestrating a diversified portfolio across pharmaceuticals, nutraceuticals, consumer products, and medical devices. It has cultivated a unique philosophy: a balance between large-scale operations and niche markets. The company’s pharmaceutical sector, its most significant revenue contributor, is driven largely by advancements in CNS (central nervous system) treatments and nephrology. The success of its flagship product, Abilify, a leading antipsychotic, underscores Otsuka’s ability to combine market demands with cutting-edge research to sustain growth and profitability. In parallel, Otsuka nurtures its nutraceuticals wing, embodied by its signature Pocari Sweat and SoyJoy brands. These products epitomize the company’s strategy of creating and expanding niche markets, offering health-oriented products that resonate with evolving consumer health trends. This diversification into consumer products and nutraceuticals not only complements its pharmaceutical endeavors but also mitigates risks by tapping into varied revenue streams. By focusing on health and wellness broadly, Otsuka Holdings strategically positions itself to navigate the complexities of the global healthcare market, ensuring a resilient business model. Through this multifaceted approach, Otsuka sustains its growth, reaffirming its legacy as a dynamic and globally influential company.
See Also
What is Otsuka Holdings Co Ltd's Revenue?
Revenue
2.3T
JPY
Based on the financial report for Dec 31, 2024, Otsuka Holdings Co Ltd's Revenue amounts to 2.3T JPY.
What is Otsuka Holdings Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
4%
Over the last year, the Revenue growth was 15%. The average annual Revenue growth rates for Otsuka Holdings Co Ltd have been 16% over the past three years , 11% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet